V
Vivos Therapeutics, Inc.
VVOSCIK 0001716166NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
$17.44M
Net Income
$-21.20M
Total Assets
$25.15M
Equity
$-1.49M
Shares Out
13.49M
Op. Cash Flow
$-15.30M
Business
Vivos Therapeutics, Inc. develops and commercializes dental and medical appliances and treatment protocols for sleep-disordered breathing using The Vivos Method. Its main products and services include Vivos appliances, related diagnostic and therapeutic services, and associated training and support for healthcare providers. The company operates an alliance marketing and acquisition model, including an M&A Group (formerly Medical Integration Division) to form Dental Service Organizations (DSOs), Medical Service Organizations (MSOs), and other partnerships. It distributes products and services through dentists, medical professionals, and contract manufacturers in the United States and internationally.
Summary from filing dated 2025-03-31
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 17 | 15 | 14 | 16 | 17 | |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 7 | 6 | 6 | 6 | 4 | |
| Gross profit | 11 | 9 | 8 | 10 | 13 | |
| General and administrative | 28 | 18 | 22 | 29 | 26 | |
| Sales and marketing | 1 | 2 | 2 | 5 | 6 | |
| Depreciation and amortization | 1 | 581,000 | 621,000 | 669,000 | 733,000 | |
| Total operating expenses | 30 | 20 | 26 | 35 | 33 | |
| Operating loss | −20 | −11 | −17 | −25 | −20 | |
| Other expense | −1 | −110,000 | −212,000 | −190,000 | −9,000 | |
| Other income | 145,000 | 145,000 | 147,000 | 89,000 | — | |
| Loss before income taxes | −21 | −11 | −14 | −24 | −20 | |
| Net loss | −21 | −11 | — | — | — | |
| Net loss attributable to non-controlling interest | −60,000 | — | — | — | — | |
| Net loss attributable to stockholders | −21 | −11 | −14 | −24 | −20 | |
| Net loss per share (basic) | −2.07 | −2.22 | −11.14 | −25.9 | −0.96 | |
| Net loss per share (diluted) | −2.07 | −2.22 | −11.14 | −25.9 | — | |
| Weighted average number of shares of Common Stock outstanding (basic) | 10 | 5 | 1 | 920,592 | 21,233 | |
| Weighted average number of shares of Common Stock outstanding (diluted) | 10 | 5 | 1 | 920,592 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 6 | 2 | 4 | 24 | |
| Accounts receivable, net of allowance of $882 and $390, respectively | 2 | 430,000 | 202,000 | 457,000 | 1 | |
| Prepaid expenses and other current assets | 774,000 | 783,000 | 616,000 | 1 | 2 | |
| Total current assets | 4 | 7 | 2 | 5 | 27 | |
| Goodwill | 9 | 3 | 3 | 3 | 3 | |
| Property and equipment, net | 4 | 3 | 3 | 3 | 3 | |
| Operating lease right-of-use asset | 4 | 1 | 1 | 2 | — | |
| Intangible assets, net | 4 | 409,000 | 420,000 | 302,000 | 341,000 | |
| Deposits and other | 228,000 | 216,000 | 307,000 | 374,000 | 356,000 | |
| Total assets | 25 | 15 | 11 | 14 | 34 | |
| Accounts payable | 2 | 1 | 2 | 1 | 920,000 | |
| Accrued expenses | 6 | 2 | 2 | 2 | 3 | |
| Current portion of contract liabilities | 479,000 | 896,000 | 2 | 3 | 2 | |
| Current portion of operating lease liability | 672,000 | 477,000 | 474,000 | 419,000 | — | |
| Current portion of financing lease liability | 55,000 | — | — | — | — | |
| Current portion of debt | 8 | — | — | — | 1 | |
| Other current liabilities | 850,000 | 273,000 | 198,000 | 145,000 | — | |
| Total current liabilities | 18 | 5 | 7 | 7 | 8 | |
| Contract liabilities, net of current portion | — | 97,000 | 289,000 | 112,000 | — | |
| Employee retention credit liability | 3 | 1 | 1 | — | — | |
| Operating lease liability, net of current portion | 4 | 1 | 2 | 2 | — | |
| Financing lease liability, net of current portion | 113,000 | — | — | — | — | |
| Debt, net of current portion | 469,000 | — | — | — | — | |
| Other liabilities | 1 | — | — | — | — | |
| Total liabilities | 27 | 7 | 10 | 9 | 8 | |
| Commitments and contingencies (Note 14) | — | — | — | — | — | |
| Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; no shares issued and outstanding | — | — | — | — | — | |
| Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 9,286,609 shares as of December 31, 2025 and 5,889,520 shares as December 31, 2024 | 1,000 | — | — | — | 2,000 | |
| Additional paid-in capital | 124 | 112 | 93 | 84 | 81 | |
| Accumulated deficit | −125 | −104 | −93 | −79 | −56 | |
| Total stockholders equity/(deficit) | −1 | 8 | 411,000 | 5 | 26 | |
| Non-controlling interest | 60,000 | — | — | — | — | |
| Total equity/(deficit) | −2 | 8 | 411,000 | — | — | |
| Total liabilities and equity/(deficit) | 25 | 15 | 11 | 14 | 34 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 661,000 | 762,000 | 1 | 2 | 3 | |
| Depreciation and amortization | 1 | 581,000 | 621,000 | 669,000 | 733,000 | |
| Fair value of common stock issued for services | — | 11,000 | 87,000 | — | 20,000 | |
| Fair value of warrants issued for services | — | 31,000 | 737,000 | 711,000 | 232,000 | |
| Accounts receivable, | −217,000 | −228,000 | 255,000 | 746,000 | 228,000 | |
| Operating lease liabilities, net | 55,000 | −129,000 | −109,000 | 7,000 | 548,000 | |
| Prepaid expenses and other current assets | 19,000 | −167,000 | 832,000 | 126,000 | −902,000 | |
| Deposits | 29,000 | 105,000 | 80,000 | −16,000 | −47,000 | |
| Accounts payable | 524,000 | −1 | 734,000 | 491,000 | 139,000 | |
| Accrued expenses | 4 | −39,000 | 422,000 | −941,000 | 1 | |
| Other liabilities | 483,000 | — | 41,000 | 144,000 | — | |
| Contract liability | −514,000 | −1 | −611,000 | 638,000 | −539,000 | |
| Net cash used in operating activities | −15 | −13 | −12 | −20 | −16 | |
| Acquisitions of property and equipment | −2 | −568,000 | −803,000 | −924,000 | −2 | |
| Cash paid for acquisition of SCN | −5 | — | −50,000 | — | — | |
| Net cash used in investing activities | −8 | −568,000 | −853,000 | −924,000 | −3 | |
| Proceeds from issuance of common stock | 6 | 8 | 4 | — | 28 | |
| Proceeds from issuance of debt | 11 | — | — | — | — | |
| Proceeds from issuance of warrants | 2 | 8 | — | — | — | |
| Proceeds from issuance of pre-funded warrants | 609,000 | 4 | 8 | — | — | |
| Proceeds from exercise of warrants | 866,000 | — | — | — | — | |
| Payments for issuance costs | −837,000 | −1 | −1 | — | −2 | |
| Reduction of finance lease liability | −28,000 | — | — | — | — | |
| Net cash provided by financing activities | 19 | 18 | 11 | — | 24 | |
| Net increase (decrease) in cash and cash equivalents | −4 | 5 | −2 | −21 | 6 | |
| Cash paid for interest | — | 9,000 | — | — | 18,000 | |
| Conversion of promissory note, net of issuance costs | 1 | — | — | — | — | |
| Common stock issued as consideration for acquisition | 1 | — | — | — | — | |
| Contingent consideration as consideration for acquisition of SCN, net of valuation adjustment | 1 | — | — | — | — | |
| Fair value of warrants issued in private placement | — | 262,000 | — | — | — | |
| Acquisitions of property and equipment by issuing debt | 922,000 | — | — | — | — | |
| Conversion of debt to equity | 25,000 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro